Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

Recent & Breaking News (TSXV:CLAS.H)

Kalytera Announces Closing of Private Placement of Convertible Debenture Units

GlobeNewswire March 7, 2019

Kalytera Announces Initiation of Study KAL-07 – Food Effect Study

GlobeNewswire March 6, 2019

Kalytera Announces Private Placement of Convertible Debenture Units

GlobeNewswire March 5, 2019

Kalytera Announces Share Issuance for January Invoices under Payments Agreements with Salzman Group

GlobeNewswire February 26, 2019

Kalytera Completes Deferral Transaction with Former Shareholders of Talent Biotechs

GlobeNewswire February 8, 2019

Kalytera Reports Additional Positive Data for CBD in Prevention of Acute GVHD

GlobeNewswire February 5, 2019

KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

PR Newswire February 1, 2019

Kalytera Announces Change to Scope of Services under Payments Agreements with Salzman Group and Next Share Issuance

GlobeNewswire January 31, 2019

Kalytera Announces Grant of Stock Options to Certain Directors and Employees

GlobeNewswire January 28, 2019

Kalytera Announces Closing of Private Placement of Common Shares and Common Share Purchase Warrants

GlobeNewswire January 15, 2019

A Hot Buy: Pharma Pioneer Kalytera Financing CBD Treatments

Stockhouse Editorial January 15, 2019

Kalytera Announces Initiation of Research Coverage by Echelon Wealth Partners

GlobeNewswire January 15, 2019

Kalytera Announces Share Issuance and Extension to March 1 under Payments Agreements with Salzman Group

GlobeNewswire January 14, 2019

Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

GlobeNewswire January 11, 2019

Kalytera Announces Positive Phase 2 CBD Test Results

Stockhouse Editorial December 20, 2018

Update on Phase 2 Clinical Study: CBD in Prevention of Acute GVHD

Featured Press Release December 20, 2018

Kalytera Provides Update on Phase 2 Clinical Study Evaluating CBD in Prevention of Acute GVHD

Stockhouse.com December 20, 2018

Kalytera Announces Private Placement of Common Shares and Common Share Purchase Warrants

GlobeNewswire December 18, 2018

Kalytera Announces Additional Share Issuance for Services under Payments Agreement with Salzman Group

GlobeNewswire December 4, 2018